Is FMC Stock Going to $15?

Adjusted revenue declined 5% to $3.5B and FMC reported a GAAP loss from continuing operations of $2.2B versus a $403.4M profit a year earlier. Management expects roughly a 5% revenue decline this year, shares are down 68.5% over the last year and closed at $13.09 on March 20; a $15 target implies ~15% premium to current price. The stock trades at a P/S of 0.5 (down from 1.2 a year ago); absent an acquisition, achieving $15 would require ~15% sales-per-share growth or roughly a doubling of the P/S multiple, both unlikely given guidance. Company is exploring strategic options, including a potential sale, but valuation and operational headwinds make a deal or turnaround uncertain.

Analysis

The company's current episode — suppressed margins, heavy one-offs and a liquidity-strained narrative — typically compresses trading multiples well below peer averages and creates a two-way event: potential strategic interest from buyers looking to cherry-pick assets, and elevated downside if operational fixes stall. Strategics and PE prefer buying portfolios with steady EBITDA and regulatory-clearable chemistries; expect any true sale to be asset-by-asset or a carve-up rather than a quick whole-company takeout, which lengthens the timeline and increases execution risk.

Second-order winners include specialty intermediates producers and distributors that can absorb volume shifts from a reconfigured product portfolio; losers are small contract manufacturers and single-crop-exposure dealers who rely on high-margin crop-protection SKUs. Crop-cycle seasonality is an underappreciated near-term throttle — anemic planting demand or a negative commodity-price shock will amplify destocking and force deeper discounting into the next reporting quarter.

Key catalysts run on three horizons: near-term (days–weeks) for restructuring or CIO/board announcements and earnings beats/misses; medium-term (3–12 months) for Q-season demand and potential asset-sale teasers; long-term (12–36 months) for realized cost-savings, pipeline rehabbing, or completed M&A outcomes. Tail risks that could materially change the thesis include regulatory bans on core chemistries, an activist/white-knight that accelerates a sale process, or a macro shock to farm incomes — any of which can swing valuation materially in either direction.

Key Decisions for Investors

• Relative-value pair: Short FMC equity vs long CTVA (Corteva) — size the pair to be dollar-neutral and target 6–12 month horizon. Rationale: isolates company-specific execution and balance-sheet risk while keeping exposure to any sector-wide rebound. Risk management: stop if the spread reverses >25% or after a takeover bid on FMC.
• Event-driven option play: Buy FMC 9–12 month put spreads (long puts and sell lower-strike puts) to cap premium outlay while keeping asymmetric downside if operational news disappoints; alternative: buy calls after a credible asset-sale announcement to play takeover premium. Target payoff: 2–4x on realized downside vs defined max loss = net premium.
• Credit-focused trade: Buy protection/short bonds (or add credit spreads) on FMC 1–3 year paper where available; expected payoff if restructuring or distressed-sale pricing emerges. Timeframe: 12–24 months. Risk: illiquidity and recovery value in a structured sale could limit upside, so position size accordingly (<2% NAV).